Vaccine To Prevent Influenza Virus And Bacterial Super-infection.
Funder
National Health and Medical Research Council
Funding Amount
$707,717.00
Summary
Influenza viruses have the ability to pre-dispose infected hosts toward secondary bacterial complications. The mortality of viral infections that are complicated by a concurrent, or subsequent, bacterial infection (known as a super-infection), is often greater than that of either the virus or the bacteria alone. We will develop a novel multi-pathogen vaccine candidate against the major upper respiratory tract pathogens - Influenza A and Streptococcus pyogenes to prevent super-infections.
HARNESSING T CELL QUALITY FOR PANDEMIC PREPAREDNESS
Funder
National Health and Medical Research Council
Funding Amount
$503,146.00
Summary
Developing highly effective vaccines is critical to rapidly combat global pandemics. To generate a protective antibody response against novel viruses, a vaccine must elicit a targeted B cell response supported by effective CD4 T cell help. We propose that existing CD4 T cell memory can be harnessed to rapidly and effectively support B cell responses to novel vaccine candidates. This work will contribute to pandemic preparedness strategies and improve the development pathway for new vaccines.
Using Immunological Principles To Inform Malaria Vaccine Design
Funder
National Health and Medical Research Council
Funding Amount
$577,763.00
Summary
Malaria kills ~420,000 people each year worldwide. While a vaccine does exist, efficacy is poor and protection wanes rapidly. We have made breakthroughs in understanding the immune response to malaria that allow us to design a new generation of malaria vaccines. Based on this we aim to generate a vaccine that induces sustained levels of high-quality antibodies targeting multiple targets on the parasite and so can provide sustained long-term protection.
Gamma Delta T Cells: The Fourth Player In CD8 T Cell Immunity
Funder
National Health and Medical Research Council
Funding Amount
$1,020,777.00
Summary
The immune systems of animals have evolved complex but effective mechanisms to protect against infection with intracellular pathogens. This requires that T cells can distinguish uninfected cells from those harbouring pathogens. This is achieved via recognition of pathogen-derived molecules, which activate the immune system to recognise and fight the pathogen. We have identified a crucial role for a gamma delta T cells in this process, making them essential sentinels of intracellular infection.
Immunomodulatory Vaccines In The Treatment Of Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$678,899.00
Summary
Peanut allergy is the most common cause of food-induced anaphylactic reactions in Australia and is a major burden to our healthcare system. Current clinical practice advice dietary avoidance to prevent fatal anaphylactic responses. We propose the use of an immunomodulatory vaccine to re-write the immune response to peanut antigens, from an allergic to a tolerant phenotype. This study will provide novel insights into rational approaches for manipulating immune memory to food allergens.
Developing An In Vitro Model Of A Human Blastocyst
Funder
National Health and Medical Research Council
Funding Amount
$890,062.00
Summary
Using novel cellular and molecular technologies we propose to develop an artificial model of an early human blastocyst. This will allow us to study the first initial steps in human development without the use of real embryos. Such a model will not only help us decipher the first steps in human development, but we anticipate it will be essential to study how gene mutations and the environment affect this initial step in human development.
Growth Factor Directed Developmental And Pathological Lymphangiogenesis
Funder
National Health and Medical Research Council
Funding Amount
$1,048,507.00
Summary
The formation of new lymphatic vessels occurs in normal development and in diseased tissues in cancer and cardiovascular disease. We have developed an understanding of how lymphatics form in development but we understand far less about how they form in disease. This project will apply multidisciplinary approaches, including genetics and computational biology, to compare how lymphatics form in development and disease. We hope to uncover new ways to manipulate this process for therapeutic gain.
Relaxin Receptor Structural Determination To Aid Therapeutic Development
Funder
National Health and Medical Research Council
Funding Amount
$1,249,114.00
Summary
The receptor for the peptide hormone relaxin, RXFP1, is being targeted by numerous drug companies for the treatment of cardiovascular disease. However, the lack of molecular detail of how relaxin binds and activates RXFP1 is hindering new drug development. We will determine the structure of the complex of relaxin bound to RXFP1 and the mechanism by which this activates cells. The knowledge gained will aid in the design of new drugs targeting RXFP1 for the treatment of cardiovascular disease.
Harnessing The Benefits Of Autonomous Vehicles For Health
Funder
National Health and Medical Research Council
Funding Amount
$738,596.00
Summary
The arrival of autonomous vehicles (AVs) will have huge implications for health behaviours, including physical activity and diet. It is critical that appropriate planning processes are undertaken as early as possible to prevent cities of the future being designed around AVs rather than people, thereby losing the potential for this new technology to be harnessed as a means of enhancing health. This project will facilitate the inclusion of health considerations in AV implementation processes.
Reprogramming Human Fibroblasts Into Induced Trophoblast Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$889,064.00
Summary
We have been able to generate artificial human trophectoderm which is the tissue that creates the placenta. This will allow us to do research in how the genes control the fate of these cells without the need of human embryos or placenta. We anticipate that the derivation and characterising these cells will revolutionise placenta research, which in turn will contribute to the establishment of new therapies for placenta disease and infertility.